Jubilant Pharmova FY26 Revenue Up 14% to ₹8,280 Cr

Jubilant Pharmova reported FY26 revenue growth of 14% YoY to ₹8,280 Cr and proposed a dividend of ₹5 per share.
CDMO Sterile Injectables revenue surged 38% driven by Line 3 ramp-up; onboarded a major global oncology product.
Radiopharma margins declined due to Montreal facility shutdown; production to normalize from H2FY27 onwards.
Company maintains Net Debt/EBITDA at 1.3x while investing in capacity expansion across key business segments.